Semax
Semax is a nootropic peptide popular in cognitive-performance communities, but pharmacy access is still constrained by current FDA positioning.
Current status
Restricted
Cognitive support, with current federal compounding constraints still in play.
FDA category
Category 2
Can pharmacies compound this?
No
Reclassification expected?
Yes
Often paired with Selank in market conversations about future access changes.
Primary Use
Cognitive support
Regulatory Timeline
Mar 15, 2023
FDA peptide compounding scrutiny intensified across 503A and 503B channels.
Sep 29, 2023
Current status signal recorded: Nootropic peptide demand increased despite restrictive compounding treatment..
Feb 27, 2026
Political pressure and market expectations increased around a future peptide reclassification review.
Get notified...
Get notified when Semax status changes
State-specific notes
Florida
Availability changes quickly with pharmacy policy.